RT Journal Article
SR Electronic
T1 SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.05.20169169
DO 10.1101/2020.08.05.20169169
A1 Shahjouei, Shima
A1 Tsivgoulis, Georgios
A1 Farahmand, Ghasem
A1 Koza, Eric
A1 Mowla, Ashkan
A1 Sadr, Alireza Vafaei
A1 Kia, Arash
A1 Far, Alaleh Vaghefi
A1 Mondello, Stefania
A1 Cernigliaro, Achille
A1 Ranta, Annemarei
A1 Punter, Martin
A1 Khodadadi, Faezeh
A1 Sabra, Mirna
A1 Ramezani, Mahtab
A1 Naderi, Soheil
A1 Olulana, Oluwaseyi
A1 Chaudhary, Durgesh
A1 Lyoubi, Aicha
A1 Campbell, Bruce
A1 Arenillas, Juan F.
A1 Bock, Daniel
A1 Montaner, Joan
A1 Neshin, Saeideh Aghayari Sheikh
A1 de Sousa, Diana Aguiar
A1 Tenser, Matthew S.
A1 Aires, Ana
A1 Alfonso, Merccedes De Lera
A1 Alizada, Orkhan
A1 Azevedo, Elsa
A1 Goyal, Nitin
A1 Babaeepour, Zabihollah
A1 Banihashemi, Gelareh
A1 Bonati, Leo H.
A1 Cereda, Carlo
A1 Chang, Jason J.
A1 Crnjakovic, Miljenko
A1 De Marchis, GianMarco
A1 Del Sette, Massimo
A1 Ebrahimzadeh, Seyed Amir
A1 Farhoudi, Mehdi
A1 Gandoglia, Ilaria
A1 Gonçalves, Bruno
A1 Griessenauer, Christoph
A1 Hancı, Mehmet Murat
A1 Katsanos, Aristeidis H.
A1 Krogias, Christos
A1 Leker, Ronen
A1 Lotman, Lev
A1 Mai, Jeffrey
A1 Male, Shailesh
A1 Malhotra, Konark
A1 Malojcic, Branko
A1 Mesquita, Teresa
A1 Mirghasemi, Asadollah
A1 Aref, Hany Mohamed
A1 Afshar, Zeinab Mohseni
A1 Moon, Jusun
A1 Niemelä, Mika
A1 Jahromi, Behnam Rezaei
A1 Nolan, Lawrence
A1 Pandhi, Abhi
A1 Park, Jong-Ho
A1 Marto, João Pedro
A1 Purroy, Francisco
A1 Ranji-Burachaloo, Sakineh
A1 Carreira, Nuno Reis
A1 Requena, Manuel
A1 Rubiera, Marta
A1 Sajedi, Seyed Aidin
A1 Sargento-Freitas, João
A1 Sharma, Vijay
A1 Steiner, Thorsten
A1 Tempro, Kristi
A1 Turc, Guillaume
A1 Ahmadzadeh, Yassaman
A1 Almasi-Dooghaee, Mostafa
A1 Assarzadegan, Farhad
A1 Babazadeh, Arefeh
A1 Baharvahdat, Humain
A1 Cardoso, Fabricio
A1 Dev, Apoorva
A1 Ghorbani, Mohammad
A1 Hamidi, Ava
A1 Hasheminejad, Zeynab Sadat
A1 Komachali, Sahar Hojjat-Anasri
A1 Khorvash, Fariborz
A1 Kobeissy, Firas
A1 Mirkarimi, Hamidreza
A1 Mohammadi-Vosough, Elahe
A1 Misra, Debdipto
A1 Noorian, Ali Reza
A1 Nowrouzi-Sohrabi, Peyman
A1 Paybast, Sepideh
A1 Poorsaadat, Leila
A1 Roozbeh, Mehrdad
A1 Sabayan, Behnam
A1 Salehizadeh, Saeideh
A1 Saberi, Alia
A1 Sepehrnia, Mercedeh
A1 Vahabizad, Fahimeh
A1 Yasuda, Thomas
A1 Marvast, Ahmadreza Hojati
A1 Ghabaee, Mojdeh
A1 Rahimian, Nasrin
A1 Harirchian, Mohammad Hossein
A1 Borhani-Haghighi, Afshin
A1 Arora, Rohan
A1 Ansari, Saeed
A1 Avula, Venkatesh
A1 Li, Jiang
A1 Abedi, Vida
A1 Zand, Ramin
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.05.20169169.abstract
AB Background Stroke is reported as a consequence of SARS-CoV-2 infection. However, there is a lack of regarding comprehensive stroke phenotype and characteristicsMethods We conducted a multinational observational study on features of consecutive acute ischemic stroke (AIS), intracranial hemorrhage (ICH), and cerebral venous or sinus thrombosis (CVST) among SARS-CoV-2 infected patients. We further investigated the association of demographics, clinical data, geographical regions, and countries’ health expenditure among AIS patients with the risk of large vessel occlusion (LVO), stroke severity as measured by National Institute of Health stroke scale (NIHSS), and stroke subtype as measured by the TOAST criteria. Additionally, we applied unsupervised machine learning algorithms to uncover possible similarities among stroke patients.Results Among the 136 tertiary centers of 32 countries who participated in this study, 71 centers from 17 countries had at least one eligible stroke patient. Out of 432 patients included, 323(74.8%) had AIS, 91(21.1%) ICH, and 18(4.2%) CVST. Among 23 patients with subarachnoid hemorrhage, 16(69.5%) had no evidence of aneurysm. A total of 183(42.4%) patients were women, 104(24.1%) patients were younger than 55 years, and 105(24.4%) patients had no identifiable vascular risk factors. Among 380 patients who had known interval onset of the SARS-CoV-2 and stroke, 144(37.8%) presented to the hospital with chief complaints of stroke-related symptoms, with asymptomatic or undiagnosed SARS-CoV-2 infection. Among AIS patients 44.5% had LVO; 10% had small artery occlusion according to the TOAST criteria. We observed a lower median NIHSS (8[3-17], versus 11 [5-17]; p=0.02) and higher rate of mechanical thrombectomy (12.4% versus 2%; p<0.001) in countries with middle to high-health expenditure when compared to countries with lower health expenditure. The unsupervised machine learning identified 4 subgroups, with a relatively large group with no or limited comorbidities.Conclusions We observed a relatively high number of young, and asymptomatic SARS-CoV-2 infections among stroke patients. Traditional vascular risk factors were absent among a relatively large cohort of patients. Among hospitalized patients, the stroke severity was lower and rate of mechanical thrombectomy was higher among countries with middle to high-health expenditure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was designed by the investigators at the Neuroscience Institute of Geisinger Health System, Pennsylvania, USA, and received approval by the Institutional Review Board of Geisinger Health System and other participating institutions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable upon request